France Dube, Director Global Policy of Precision Medicine and Breast Cancer at AstraZeneca, shared a post on LinkedIn:
“On the heels of the San Antonio Breast Cancer Symposium (SABCS) and in the final weeks of 2025, I’ve been reflecting on the progress we’ve made this year toward advancing breast cancer care and outcomes – including the development and publication of the Breast Cancer Care Quality Index (BCCQI) in ecancer.
This achievement is the result of a true collective effort involving patients, advocates, clinicians, policymakers, researchers, industry partners, and more.
I’m grateful for the opportunities we’ve had this year to convene – from the Concordia Annual Summit to ESMO, ABC8 and the WCLS, and now SABCS – united by a shared goal of advancing equitable breast cancer care for all women.
A special thanks to our Global Breast Cancer Care Council members and all of the esteemed authors of the BCCQI, whose advocacy and engagement continue to elevate breast cancer as a global health priority and champion the adoption of the BCCQI.
If you haven’t yet explored it, I encourage you to read the recent breast cancer policy report from Concordia and AstraZeneca. It shines a light on the inequities impacting women’s health and offers tangible solutions to remove barriers and improve outcomes for all women, everywhere.
Read the report.
More posts featuring SABCS 2025.